Search
Search
Deborah Ristvedt, DO; Douglas McGraw, DO; and Arkadiy Yadgarov, MD
Show Description +
Watch as Deborah Ristvedt, DO; Douglas McGraw, DO; and Arkadiy Yadgarov, MD share insights into the evolving landscape of glaucoma care. This engaging discussion highlights the benefits of interventional glaucoma, the role of MIGS and canal surgery, and how proactive treatment strategies are reshaping patient outcomes. The video also features real-world case discussions and discover how the OMNI® Edge is being used in patients with primary open-angle glaucoma (POAG), and explores the growing impact of interventional approaches in today’s modern glaucoma management. ––––– OMNI Edge is indicated for canaloplasty followed by trabeculotomy to reduce intraocular pressure in adult patients with primary open-angle glaucoma. Visit sightsciences.com/omniedge for full instructions for use, warnings, precautions, and adverse event information. All rights reserved. 07/2025 OM-3539-US.v1
Posted: 8/20/2025
Deborah Ristvedt, DO; Douglas McGraw, DO; and Arkadiy Yadgarov, MD
Watch as Deborah Ristvedt, DO; Douglas McGraw, DO; and Arkadiy Yadgarov, MD share insights into the evolving landscape of glaucoma care. This engaging discussion highlights the benefits of interventional glaucoma, the role of MIGS and canal surgery, and how proactive treatment strategies are reshaping patient outcomes. The video also features real-world case discussions and discover how the OMNI® Edge is being used in patients with primary open-angle glaucoma (POAG), and explores the growing impact of interventional approaches in today’s modern glaucoma management. ––––– OMNI Edge is indicated for canaloplasty followed by trabeculotomy to reduce intraocular pressure in adult patients with primary open-angle glaucoma. Visit sightsciences.com/omniedge for full instructions for use, warnings, precautions, and adverse event information. All rights reserved. 07/2025 OM-3539-US.v1
Posted: 8/20/2025
The Crucial Choice in Combating Glaucoma With Interventional Treatment
MIGS Beyond Cataract Surgery: An Interventional Mindset
Nine Reasons Why We Perform MIGS with OMNI
_1657116947.jpg)
MIGS Beyond Cataract Surgery
Spotlight on OMNI in Standalone Procedures
The Benefits of OMNI in Pseudophakic Patients
MIGS Algorithm: Navigating A Myriad of Decisions
The Changing MIGS Landscape
OMNI Surgical System: My First 10 Patients
About Sight Sciences
At Sight Sciences, we are reimagining eyecare with transformative technology and an interventional mindset. We believe interventions should happen sooner to preserve, protect, or restore natural eye function. So, we aim to provide eyecare providers with transformative, clinically-proven therapies that are intuitive, less invasive, and more intelligent. Our mission is clear: to develop transformative, interventional technologies that allow eyecare providers to procedurally elevate the standards of care – empowering people to keep seeing
Explore more at sightsciences.com
Follow Sight Sciences
IMPORTANT PRODUCT INFORMATION:
The OMNI® Surgical System is indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm’s canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma. Do not use the OMNI® in any situations where the iridocorneal angle is compromised or has been damaged (e.g., from trauma or surgery), since it may not be possible to visualize the angle or to properly pass the microcatheter. Do not use the OMNI® in patients with angle recession; neovascular glaucoma; chronic angle closure; narrow-angle glaucoma; traumatic or malignant glaucoma; or narrow inlet canals with plateau iris. Do not use the OMNI® Surgical System in quadrants with previous MIGS implants. Visit omnisurgical.com/ifu for the indications for use, contraindications, warnings, and potential adverse events.
Doctors are paid consultants of Sight Sciences, Inc.
© 2025 Sight Sciences. Sight Sciences, the Sight Sciences logo, and OMNI are registered trademarks of Sight Sciences. 04/2025 OM-1129-US.v4
_1748562763.jpg?auto=compress,format&w=180)
